Newsfeeds Archive - Page 7 of 7

2 minute read

Earnings

Looking Into Neurocrine Biosciences’s Return On Capital Employed

November 9, 10:54 AM

According to Benzinga Pro, during Q3, Neurocrine Biosciences (NASDAQ:NBIX) earned $68.50 million, a 505.33% increase from the preceding quarter. Neurocrine Biosciences also posted a total of $387.90 million in sales, a 2.56% increase since Q2.

NBIX

1 minute read

JP Morgan Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $143

By Benzinga Newsdesk

November 3, 10:15 AM

JP Morgan analyst Anupam Rama maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and raises the price target from $138 to $143.

NBIX

1 minute read

SVB Leerink Maintains Market Perform on Neurocrine Biosciences, Raises Price Target to $115

By Benzinga Newsdesk

November 2, 5:04 AM

SVB Leerink analyst Marc Goodman maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Market Perform and raises the price target from $100 to $115.

NBIX

1 minute read

Neurocrine Biosciences Buys UK-Based Hormone Therapy Player

By Vandana Singh

August 30, 12:23 PM

Neurocrine Biosciences Inc (NASDAQ:NBIX) has agreed to pay £48.3 million for the U.K. hormone therapy group, Diurnal Group Plc. The 27.5p share…

NBIX

1 minute read

Neurocrine Biosciences Shares Jump After Raising Ingrezza Sales Guidance

By Vandana Singh

August 5, 11:33 AM

Tucked in its Q2 earning release, Neurocrine Biosciences Inc (NASDAQ:NBIX) said that in August, the Phase 2a study of NBI-827104…

NBIX

1 minute read

Neurocrine Biosciences Q2 EPS $0.84 Beats $0.59 Estimate, Sales $378.20M Beat $341.31M Estimate

By Benzinga Newsdesk

August 4, 4:57 PM

Neurocrine Biosciences (NASDAQ:NBIX) reported quarterly earnings of $0.84 per share which beat the analyst consensus estimate of $0.59 by 42.37 percent. This is a 33.33 percent increase over earnings of $0.63 per share

NBIX

34 minute read

Earnings

Earnings Scheduled For August 4, 2022

By Benzinga Insights

August 4, 4:23 AM

Companies Reporting Before The Bell • Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.

AAOI

1 minute read

Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $102

By Benzinga Newsdesk

July 15, 11:40 AM

Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-Weight and raises the price target from $100 to $102.

NBIX

1 minute read

Needham Previews Neurocrine’s Upcoming Mid-Stage Data from Essential Tremor Study

By Vandana Singh

July 11, 2:20 PM

Needham previews the upcoming Phase 2 data readout for Neurocrine Biosciences Inc's (NASDAQ: NBIX) NBI-827104, a t-type calcium channel blocker in essential tremor (ET), by mid-2022.

JAZZ